VERTEX PHARMACEUTICALS INC. REGISTERED SHARES DL -,01
Technische Signale
| Signale Details | |
|---|---|
| WKN / ISIN | - / US92532F1003 |
| Börse | Berlin |
| Schluss | 426,80 |
| Konservatives Signal |  17.09.24 |
| MACD |  09.05.24 |
| Momentum | 16.05.24 |
| Bollinger Bands | 09.08.24 |
| TBI | 05.09.24 |
| Schnitt GD 90 | 16.09.24 |
Analystenbewertung
| Bewertungstrend | aktuell | Vorwoche | Vormonat |
|---|---|---|---|
| Bewertung | 1,97 | 1,97 | 1,97 |
| Anzahl der Analysten | 31 | 31 | 31 |
| Kaufen | 15 | 15 | 15 |
| Übergewichten | 5 | 5 | 5 |
| Halten | 9 | 9 | 9 |
| Untergewichten | 1 | 1 | 1 |
| Verkaufen | 1 | 1 | 1 |
| Aktueller Durchschnitt von insgesamt 31 Analysten: 1,97 | |||
| Planzahlen (in EUR) | 2023 | 2024(e) | 2025(e) |
|---|---|---|---|
| Umsatz | 9,87 Mrd. | 10,75 Mrd. | 11,67 Mrd. |
| EBIT | 3,45 Mio. | 621,96 Mio. | 5,50 Mrd. |
| EBITDA | 3,62 Mio. | 5,37 Mrd. | 5,84 Mrd. |
| Nettoverschuldung** | -13.237.100.000 | -13.973.600.000 | -18.591.800.000 |
Umsatz |
EBIT |
EBITDA |
Nettoverschuldung** |
| Dividende | 2023 | 2024(e) | 2025(e) |
|---|---|---|---|
| Dividende / Aktie | 0,00 EUR | 0,00 USD | 0,00 USD |
| Dividendenrendite | 0,00% | 0,00% | 0,00% |
Dividende / Aktie (in USD) |
Dividendenrendite (in %) |
||
| Analystenhäuser |
|---|
| Argus Research Company,Baird,Baptista Research,Barclays,BMO Capital Markets Equity Research,BMO Capital Markets U.S. (Historical),BofA Global Research,Brean Capital,BTIG,Canaccord Genuity,Cantor Fitzgerald & Co.,CFRA Equity Research,Chardan Capital Markets, LLC,Citadel Securities, LLC,Citigroup Inc,Credit Suisse,CRT Capital Group,Daiwa Securities Co. Ltd.,Dawson James Securities,Deutsche Bank,Equisights,Evercore ISI,Gleacher & Company, Inc.,Goldman Sachs,Guggenheim Securities, LLC,H.C. Wainwright & Co.,ISI Group Inc.,J.P. Morgan,Janney Montgomery Scott LLC,Jefferies LLC,JMP Securities,Kingswood Capital,Lazard Capital Markets,Leerink Partners LLC,Maxim Group,Morgan Stanley,Morningstar Inc.,Needham & Company,Nomura Securities Co. Ltd.,Oppenheimer & Co. Inc.,Piper Sandler Companies,Raymond James & Associates,RBC Capital Markets,Redburn Atlantic,Rodman & Renshaw, LLC,Sanford C. Bernstein & Co., LLC,Stifel, Equities Research,TD Cowen,ThinkEquity LLC,Truist Securities,UBS Investment Bank,Wedbush Securities Inc.,Wells Fargo Securities, LLC,WestPark Capital, Inc.,William Blair & Company L.L.C.,Wolfe Research, LLC.,Zephirin Group, Inc. |
| Hinweis |
|---|
|
Selected Data supplied by Standard & Poors
* Unabhängige Schätzung (Gewinnwachstum (in %)) ** Nettobargeldbestand bei negativen Schätzungen |